Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 13/20 | 0.45 |
| ▸ | EED | O75530 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30734529 | 1.00 | NPY1R (0.45) | NPY1REEDKMT2AACP1HRH3 | |
| SCHEMBL26637104 | 1.00 | NPY1R (0.45) | NPY1REEDKMT2AACP1HRH3 | |
| SCHEMBL30735500 | 1.00 | NPY1R (0.45) | NPY1REEDKMT2AACP1HRH3 | |
| SCHEMBL26637097 | 1.00 | NPY1R (0.45) | NPY1REEDKMT2AACP1HRH3 | |
| SCHEMBL30670093 | 0.96 | NPY1R (0.42) | NPY1REEDKMT2AACP1 | |
| SCHEMBL26619427 | 0.96 | NPY1R (0.42) | NPY1REEDKMT2AACP1 | |
| SCHEMBL30670075 | 0.96 | NPY1R (0.42) | NPY1REEDKMT2AACP1 | |
| SCHEMBL26619690 | 0.96 | NPY1R (0.42) | NPY1REEDKMT2AACP1 | |
| SCHEMBL26619442 | 0.96 | NPY1R (0.42) | NPY1REEDKMT2AACP1 | |
| SCHEMBL30735107 | 0.94 | NPY1R (0.43) | NPY1REEDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | TREELINE BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | NPY1R 2559/4885EED 851/4885KMT2A 1422/4885 |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | NPY1R 2559/4885EED 851/4885KMT2A 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.